FINDing the radiopharma future: Behrenbruch provides perspective on the effects of radiopharmaceutical regulatory reforms and highlights the potential of the Facilitating Innovative Nuclear Diagnostics Act to rectify access inequities and encourage commercial and clinical development.
Page 1333
Radiation safety after RAI in paraplegia: Al-Naqeeb and colleagues describe a state-of-the-art multidisciplinary approach to safe and effective management after high-activity radioactive iodine therapy in bedbound patients with metastatic thyroid cancer.
Page 1336
177Lu-PSMA (r)evolution in cancer care: Poschenrieder and colleagues explore opportunities and challenges in integrating radiopharmaceutical therapy into everyday clinical practice and suggest changes needed for acceptance as an essential part of oncologic care.
Page 1340
International benchmark for TMTV measurements: Boellaard and colleagues detail creation of a standardized total metabolic tumor volume benchmark dataset facilitating implementation as a comparable and reproducible biomarker in lymphoma.
Page 1343
Intrascan repeatability of PET metrics: Ince and colleagues quantify intrascan repeatability of time and uptake metrics in malignant lesions on [18F]FDG PET and DOTATATE PET to determine which approach provides the most time-independent assessment of tracer avidity.
Page 1349
64CuCl2 PET/CT in bladder cancer: Piccardo and colleagues evaluate the feasibility of 64CuCl2-based staging of patients with muscle-invasive bladder cancer and compare its diagnostic efficacy with those of contrast-enhanced CT and 18F-FDG PET/CT.
Page 1357
124I-omburtamab delivery in DIPG: Pandit-Taskar and colleagues report on a first-in-human study using 124I-omburtamab imaging and a localized, convection-enhanced, intratumoral delivery technique for administering radiolabeled antibody in diffuse intrinsic pontine glioma.
Page 1364
64Cu-SAR-BBN PET/CT in PCa BCR: Li and colleagues document the detection rate of 64Cu- sarcophagine-bombesin PET/CT in patients with biochemical recurrence of prostate cancer and negative or equivocal 68Ga-PSMA-11 PET/CT results.
Page 1371
Bone lesions on [68Ga]Ga-PSMA-11 PET/CT: Mainta and colleagues estimate the diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT for bone metastases and detection of equivocal lesions at initial staging or recurrence evaluation in prostate cancer.
Page 1376
Tracheobronchial uptake on 18F-DCFPyL PET/CT: Osman and colleagues research the incidence and potential etiology of tracheobronchial uptake in patients imaged with 18F-DCFPyL PET/CT for prostate cancer.
Page 1383
Metastasis-directed RT for mCRPC: Nikitas and colleagues determine whether PSMA PET/CT–guided, metastasis-directed radiotherapy can offer durable disease control with low toxicity rates in metastatic castration-resistant prostate cancer patients with limited numbers of metastases.
Page 1387
Posttreatment SPECT/CT in RPT: Yadav and colleagues assess the impact of serial posttreatment SPECT/CT on management of patients undergoing 177Lu-PSMA radiopharmaceutical therapy.
Page 1395
Neurologic symptoms after 177Lu-PSMA: Belge Bilgin and colleagues review neurologic findings in a large cohort of metastatic castration-resistant prostate cancer patients undergoing 177Lu-PSMA-617 therapy.
Page 1402
PRRT in refractory meningiomas: Severi and colleagues document their institutional outcomes for patients with progressive meningiomas treated with peptide receptor radionuclide therapy.
Page 1409
Everolimus vs. PRRT in mNETs: Fosse and colleagues report on a retrospective study comparing the efficacy and safety of everolimus and peptide receptor radionuclide therapy in metastatic neuroendocrine tumors, with additional assessment of optimal treatment sequencing.
Page 1416
MCV and hematologic toxicity: Voter and colleagues identify baseline parameters, including elevated mean corpuscular volume, predictive of hematologic severe adverse reactions with 177Lu-DOTATATE radiopharmaceutical therapy.
Page 1423
61Cu-PSMA tracers: Bernabeu and colleagues recount the successful development, in vitro and in vivo characterization, preclinical studies, and first-in-human imaging with cyclotron-produced 61Cu-labeled tracers for PSMA targeting and highlight associated advantages.
Page 1427
Theranostic agents for PCa: Ho and colleagues introduce a promising 89Zr- and 177Lu-labeled theranostic pair based on an anti-PSMA minibody with the macrocyclic chelator L804 for safer and more effective treatment and imaging in prostate cancer.
Page 1435
211At-CD45-B10 RIT for canine haplo-HCT: Frost and colleagues investigate the use of the 211At-labeled monoclonal antibody 211At-CD45-B10 as a nonmyeloablative conditioning regimen for dog-leukocyte-antigen–haploidentical hematopoietic cell transplantation.
Page 1443
EPIC-Skin study interim results: Baxi and colleagues summarize findings to date from this international phase IV study designed to assess clinic- and patient-reported outcomes with [188Re]resin therapy of basal cell and squamous cell carcinomas.
Page 1450
225Ac-ch806 therapy: Wichmann and colleagues develop a novel tumor-specific anti–epidermal growth factor receptor chimeric antibody labeled with 225Ac and assess its in vitro properties and therapeutic efficacy in murine models of glioblastoma and colorectal cancer.
Page 1456
Robustness by unrealistic augmentation: Buddenkotte and Buchert propose a “strongly unrealistic data augmentation” technique to improve the robustness of convolutional neural networks for automatic classification of dopamine transporter SPECT.
Page 1463
Targeted α-therapy for amyloid-β: Bender and colleagues explore the hypothesis that targeted α-therapy can be used to break covalent bonds within amyloid-β aggregates and facilitate natural plaque clearance mechanisms, with implications for treatment development in Alzheimer disease.
Page 1467
Classifying and quantifying tau PET: Gebre and colleagues describe an automated method developed with machine learning for quantifying the heterogeneous burden of tau deposition as a single number with potential clinical utility in Alzheimer disease.
Page 1473
Total-body kinetic modeling of [18F]F-AraG: Omidvari and colleagues provide preliminary data on total-body pharmacokinetics of this molecular imaging tracer targeting activated T cells as a potential quantitative biomarker for assessing and predicting response in immunotherapies.
Page 1481
Anthropomorphic brain phantom: Pirozzi and colleagues introduce StepBrain, a multicompartmental anatomic brain phantom, to realistically simulate in vivo PET tracer uptake in gray matter, white matter, and striatum.
Page 1489
[177Lu]Lu-PSMA-617 during dialysis: Huang and colleagues present their experience with a patient with metastatic castration-resistant prostate cancer and bilateral nephrectomy for renal cell carcinoma who underwent 2 cycles of dose-reduced [177Lu]Lu-PSMA-617 while on hemodialysis.
Page 1493
[177Lu]Lu-DOTATE: resensitization effect: Al-Ibraheem and colleagues share a case of grade I renal carcinoid treated with lanreotide, 2 [177Lu]Lu-DOTATATE doses, and resumption of lanreotide, highlighting the possibility of resensitization in targeted therapy.
Page 1494
- © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.